MX2009008935A - Moduladores de las propiedades farmacocineticas de productos terapeuticos. - Google Patents

Moduladores de las propiedades farmacocineticas de productos terapeuticos.

Info

Publication number
MX2009008935A
MX2009008935A MX2009008935A MX2009008935A MX2009008935A MX 2009008935 A MX2009008935 A MX 2009008935A MX 2009008935 A MX2009008935 A MX 2009008935A MX 2009008935 A MX2009008935 A MX 2009008935A MX 2009008935 A MX2009008935 A MX 2009008935A
Authority
MX
Mexico
Prior art keywords
therapeutics
modulators
pharmacokinetic properties
compounds
administration
Prior art date
Application number
MX2009008935A
Other languages
English (en)
Inventor
Manoj C Desai
Hongtao Liu
Lianhong Xu
Allen Y Hong
Hon C Hui
Radall W Vivian
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39522375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009008935(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2009008935A publication Critical patent/MX2009008935A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la Fórmula IV, o u a sal farmacéuticamente aceptable, solvato, y/o éster del mismo, composiciones que contienen estos compuestos, métodos terapéuticos que incluyen la administración de tales compuestos, y métodos terapéuticos que incluyen la administración de estos compuestos con cuando menos un agente terapéutico adicional.
MX2009008935A 2007-02-23 2008-02-22 Moduladores de las propiedades farmacocineticas de productos terapeuticos. MX2009008935A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90322807P 2007-02-23 2007-02-23
US95871607P 2007-07-06 2007-07-06
PCT/US2008/054788 WO2008103949A1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics

Publications (1)

Publication Number Publication Date
MX2009008935A true MX2009008935A (es) 2009-11-02

Family

ID=39522375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008935A MX2009008935A (es) 2007-02-23 2008-02-22 Moduladores de las propiedades farmacocineticas de productos terapeuticos.

Country Status (32)

Country Link
US (7) US8148374B2 (es)
EP (5) EP3689353A1 (es)
JP (9) JP4881446B2 (es)
KR (2) KR101664154B1 (es)
CN (2) CN103435570B (es)
AP (2) AP2986A (es)
AR (1) AR065439A1 (es)
AU (1) AU2008218186C1 (es)
BR (1) BRPI0807581A2 (es)
CA (1) CA2678907C (es)
CY (9) CY1118292T1 (es)
DK (2) DK2487166T3 (es)
EA (1) EA019893B1 (es)
ES (6) ES2602784T3 (es)
FI (1) FI2487161T4 (es)
FR (1) FR20C1021I1 (es)
HK (1) HK1137451A1 (es)
HR (5) HRP20161476T4 (es)
HU (6) HUE029843T2 (es)
IL (1) IL200550A0 (es)
LT (9) LT3150586T (es)
LU (1) LUC00156I2 (es)
MX (1) MX2009008935A (es)
NO (4) NO2017002I1 (es)
NZ (1) NZ579802A (es)
PL (3) PL2487161T3 (es)
PT (6) PT2118082E (es)
SG (2) SG10201705929QA (es)
SI (1) SI3150586T1 (es)
TW (1) TWI533868B (es)
WO (1) WO2008103949A1 (es)
ZA (1) ZA200905882B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
ATE505196T1 (de) 2004-07-27 2011-04-15 Gilead Sciences Inc Nukleosid phosphonat konjugate als anti hiv mittel
KR20140004808A (ko) * 2006-07-07 2014-01-13 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
CA2661873A1 (en) * 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
PL2487166T3 (pl) 2007-02-23 2017-07-31 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
PL2487161T3 (pl) 2007-02-23 2017-03-31 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
JP2011503231A (ja) * 2007-11-20 2011-01-27 コンサート ファーマシューティカルズ インコーポレイテッド Ｈｃｖ感染処置のためのペプチド
PT2231628E (pt) * 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
SG190618A1 (en) * 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
US20100093667A1 (en) 2008-07-08 2010-04-15 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
HUE025822T2 (en) * 2009-02-06 2016-04-28 Gilead Sciences Inc Dual layer tablets containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir
AU2015200637C1 (en) * 2009-02-06 2017-08-03 Gilead Sciences, Inc. Tablets for combination therapy
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
WO2010151672A2 (en) * 2009-06-26 2010-12-29 Georgetown University Amino acid derived ureas
NZ627826A (en) 2010-01-27 2016-01-29 Viiv Healthcare Co Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
NL2005306C2 (nl) * 2010-09-02 2012-03-05 Tersia Nederland B V Koppelstuk voor meerlaagse leidingen, lasapparaaat voor het verbinden van het koppelstuk met meerlaagse leidingen, werkwijze van koppelen en een samenstel verkregen via de werkwijze.
WO2012045007A1 (en) 2010-10-01 2012-04-05 Gilead Sciences, Inc. Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
MX347512B (es) * 2010-11-19 2017-04-28 Gilead Sciences Inc Composiciones terapeuticas que comprenden hcl de rilpivirina y fumarato de disoproxilo de tenofovir.
US20130280212A1 (en) * 2010-12-21 2013-10-24 Gilead Sciences, Inc Inhibitors of cytochrome p450
US20130274254A1 (en) 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
US8987313B2 (en) 2010-12-21 2015-03-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
EP2472320A2 (en) 2010-12-30 2012-07-04 Rohm and Haas Electronic Materials LLC Compositions comprising base-reactive component and processes for photolithography
ES2543923T3 (es) * 2011-05-02 2015-08-25 Gilead Sciences, Inc. Sales sólidas amorfas de Cobicistat (GS-9350)
HUE035241T2 (en) 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination products
PE20141328A1 (es) 2011-08-16 2014-10-04 Gilead Sciences Inc Tenofovir alafenamida hemifumarato
AU2013214879A1 (en) 2012-02-03 2014-08-07 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
BR112014018918A8 (pt) * 2012-02-03 2017-07-11 Gilead Sciences Inc Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
RU2648457C2 (ru) 2012-10-23 2018-03-26 Сипла Лимитед Фармацевтическая антиретровирусная композиция
PT3608325T (pt) 2012-12-21 2022-10-17 Gilead Sciences Inc Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
EP2938603A1 (en) 2012-12-26 2015-11-04 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
NO2865735T3 (es) 2013-07-12 2018-07-21
PT3019503T (pt) 2013-07-12 2017-11-27 Gilead Sciences Inc Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv
HUE059757T2 (hu) 2013-10-07 2023-01-28 Bristol Myers Squibb Holdings Ireland Atazanavir és cobicistat formulációja HIV kezelésére
EP3077373B1 (en) 2013-12-03 2018-09-12 Mylan Laboratories Ltd. Preparation of cobicistat intermediates
WO2015145324A1 (en) 2014-03-25 2015-10-01 Mylan Laboratories Ltd Process for the preparation of cobicistat
NO2717902T3 (es) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
BR112017000922A2 (pt) * 2014-07-17 2018-01-16 Chdi Foundation, Inc. métodos e composições para tratar distúrbios relacionados ao hiv
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
PL3277691T3 (pl) 2015-04-02 2019-07-31 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
CN105198829B (zh) * 2015-08-15 2017-10-31 浙江永宁药业股份有限公司 一种可比司他中间体的制备方法及其中间体和用途
CN107513046B (zh) * 2016-06-15 2019-12-13 江苏欧信制药有限公司 一种可比司他的合成方法
EP3493797A1 (en) * 2016-08-04 2019-06-12 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
WO2018029565A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited A multi-class anti-retroviral composition
KR101908853B1 (ko) * 2017-05-17 2018-10-16 경북대학교 산학협력단 아세틸시코닌을 유효성분으로 함유하는 시토크롬 p450 동효소 억제용 조성물
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
EP3746425B1 (en) * 2018-01-30 2023-08-02 Panbela Therapeutics, Inc. Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127689A (en) * 1872-06-11 Improvement in differential pulley-blocks
US115665A (en) * 1871-06-06 Improvement in folding-steps for carriages
US143314A (en) * 1873-09-30 Improvement in condenser-tube fastenings
US191319A (en) * 1877-05-29 Improvement in stoves
US77295A (en) * 1868-04-28 theqdoee krausch
US199851A (en) * 1878-01-29 Improvement in circular saws
US108617A (en) * 1870-10-25 Improvement in ore-pulverizers
US181902A (en) * 1876-09-05 Improvement in bell toys
US99902A (en) * 1870-02-15 1870-02-15 Improvement in adjustable dials for travelers watches
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3882114A (en) 1967-10-26 1975-05-06 Oreal N-(morpholinomethyl carbamyl) cysteamine and glycine
GB1241024A (en) 1968-10-29 1971-07-28 Boehringer Sohn Ingelheim Pharmaceutical tablet base and a process for its manufacture
FR2096292A5 (es) 1970-06-15 1972-02-11 Sumitomo Chemical Co
GB1339764A (en) 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
CH586568A5 (es) 1972-04-10 1977-04-15 Hoffmann La Roche
US3957774A (en) 1972-04-17 1976-05-18 L'oreal N-morpholinomethyl-n-'-substituted ethyl and propylureas
DE2845326C2 (de) 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
HU186777B (en) 1981-07-09 1985-09-30 Magyar Tudomanyos Akademia Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them
US4603143A (en) 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2631620B1 (fr) 1988-05-19 1990-07-27 Rhone Poulenc Chimie Nouvelle silice precipitee absorbante et composition a base de cette s ilice
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5362912A (en) 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
IE913840A1 (en) 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JPH06127981A (ja) 1992-03-03 1994-05-10 Fuainiteii Kk 複合複層ガラス及びそれを使用した窓
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DE69334250D1 (de) 1992-12-29 2009-01-29 Abbott Lab Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
WO1995005808A1 (en) 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4494539B2 (ja) 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
FR2767071B1 (fr) 1997-08-06 1999-09-10 Rhodia Chimie Sa Composition comprenant un liquide absorbe sur un support a base de silice precipitee
AU2010299A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
EP1733725B2 (en) 1999-06-04 2012-08-08 Abbott Laboratories Pharmaceutical solution comprising ritonavir, a solvent (long chain fatty acid) and water
PL204924B1 (pl) 1999-10-06 2010-02-26 Tibotec Pharm Ltd Heksahydrofuro [2,3-b] furanylo-3-N-{3(1,3-benzodioksolilo-5-sulfonylo) (izobutylo) amino] -1-benzylo-2-hydroksypropylo} karbaminian oraz jego zastosowanie
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US6448245B1 (en) 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US20030035834A1 (en) 2000-05-26 2003-02-20 Pawan Seth Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
JPWO2002024167A1 (ja) 2000-09-19 2004-01-29 第一製薬株式会社 医薬組成物
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
DE10112651A1 (de) 2001-03-16 2002-09-19 Degussa Inhomogene Kieselsäuren als Trägermaterial
CZ20032959A3 (cs) 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
DE10126163A1 (de) 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
AU2002325192B2 (en) 2001-07-06 2008-05-22 Veloxis Pharmaceuticals, Inc. Controlled agglomeration
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
WO2003047551A1 (en) 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7285566B2 (en) 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
AU2003216049B2 (en) 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
US6926906B2 (en) 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
US6726448B2 (en) 2002-05-15 2004-04-27 General Electric Company Ceramic turbine shroud
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
CZ2004764A3 (cs) 2002-11-20 2005-02-16 Japan Tobacco Inc 4-Oxochinolinová sloučenina a její použití jako inhibitoru HIV-integrázy
US7189416B2 (en) 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
JP2004184681A (ja) 2002-12-03 2004-07-02 Konica Minolta Holdings Inc 熱現像感光材料
US20040224916A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CN1758901B (zh) 2003-02-19 2010-04-28 生命周期药物公司 硅石或硅石衍生物作为吸附材料的用途
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
JP4018664B2 (ja) 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
DE10337198A1 (de) 2003-08-13 2005-03-17 Degussa Ag Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2005075826A (ja) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
JP2005091988A (ja) 2003-09-19 2005-04-07 Konica Minolta Medical & Graphic Inc 熱現像感光材料及び画像形成方法
EP1675576A1 (en) 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US20050096390A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20050095287A1 (en) 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20070298108A1 (en) 2004-03-01 2007-12-27 Peter Svete Pharmaceutical Formulation
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050238675A1 (en) 2004-04-26 2005-10-27 Wenjie Li Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP3287130A1 (en) 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
JP2006003701A (ja) 2004-06-18 2006-01-05 Konica Minolta Medical & Graphic Inc 熱現像感光材料および画像形成方法
CA2572180C (en) 2004-06-28 2014-05-20 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
BRPI0512970A (pt) 2004-07-06 2008-04-22 Abbott Lab prodrogas de inibidores da hiv protease
AR045841A1 (es) 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
WO2006044968A2 (en) 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20070014854A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
CA2635468C (en) 2005-12-30 2016-08-09 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2007203715B2 (en) 2006-01-05 2012-08-02 Veloxis Pharmaceuticals A/S Disintegrating loadable tablets
KR20080110993A (ko) 2006-02-20 2008-12-22 아사히비루 가부시키가이샤 과립, 정제 및 그들의 제조방법
WO2007111866A2 (en) 2006-03-23 2007-10-04 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
KR20140004808A (ko) * 2006-07-07 2014-01-13 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
AU2007283196A1 (en) 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
CA2661873A1 (en) 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
WO2008029417A2 (en) 2006-09-04 2008-03-13 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
PL2487161T3 (pl) 2007-02-23 2017-03-31 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
TW200914011A (en) * 2007-06-29 2009-04-01 Gilead Sciences Inc Therapeutic compositions and methods
KR20100028656A (ko) 2007-06-29 2010-03-12 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
CN101796040A (zh) 2007-07-06 2010-08-04 吉里德科学公司 治疗剂的药代动力学特性调节剂
DK2245456T3 (da) 2007-12-27 2013-03-04 Baxter Int Fremgangsmåde og sammensætninger til specifik påvisning af fysiologisk acceptable polymermolekyler
SG190618A1 (en) * 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
HUE025822T2 (en) 2009-02-06 2016-04-28 Gilead Sciences Inc Dual layer tablets containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir
EP2238979A1 (en) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
KR101993491B1 (ko) 2012-01-10 2019-06-26 제이엔씨 주식회사 발광층용 재료 및 이것을 사용한 유기 전계 발광 소자
BR112014018918A8 (pt) 2012-02-03 2017-07-11 Gilead Sciences Inc Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais

Also Published As

Publication number Publication date
PT3150586T (pt) 2020-03-31
AU2008218186C1 (en) 2014-07-17
NO2017001I1 (no) 2017-01-12
CY2017001I1 (el) 2017-09-13
PL2487161T3 (pl) 2017-03-31
ZA200905882B (en) 2018-12-19
HUS1600054I1 (hu) 2017-01-30
ES2603645T3 (es) 2017-02-28
JP2014088441A (ja) 2014-05-15
LT2487161T (lt) 2016-11-10
US20100189687A1 (en) 2010-07-29
HUE031707T2 (en) 2017-07-28
US9891239B2 (en) 2018-02-13
LT2487162T (lt) 2016-11-10
AP2009004964A0 (en) 2009-10-31
LTPA2020508I1 (lt) 2020-06-25
JP6147282B2 (ja) 2017-06-14
LTC3150586I2 (lt) 2022-05-10
KR101664154B1 (ko) 2016-10-10
EA019893B1 (ru) 2014-07-30
NO2020011I1 (no) 2020-06-05
HRP20161476T1 (hr) 2016-12-16
JP2010519314A (ja) 2010-06-03
HUE029842T2 (en) 2017-04-28
EP2118082A1 (en) 2009-11-18
ES2601820T3 (es) 2017-02-16
SG10201705929QA (en) 2017-08-30
CA2678907A1 (en) 2008-08-28
CY2017003I1 (el) 2017-06-28
ES2602784T3 (es) 2017-02-22
CY2017001I2 (el) 2017-09-13
LTPA2016040I1 (lt) 2017-01-10
US20150139948A1 (en) 2015-05-21
EP2487161B2 (en) 2024-06-05
FI2487161T4 (fi) 2024-06-06
BRPI0807581A2 (pt) 2014-07-01
HRP20200349T1 (hr) 2020-06-12
PL2487162T3 (pl) 2017-03-31
US20080207620A1 (en) 2008-08-28
AR065439A1 (es) 2009-06-10
HRP20161371T1 (hr) 2016-12-02
HUS2000013I1 (hu) 2020-06-29
PL3150586T3 (pl) 2020-06-01
NZ579802A (en) 2012-04-27
EA200901155A1 (ru) 2010-02-26
NO2017002I2 (no) 2017-01-12
EP3689353A1 (en) 2020-08-05
CY2017002I1 (el) 2017-06-28
JP2016172773A (ja) 2016-09-29
JP5554300B2 (ja) 2014-07-23
CY1118227T1 (el) 2017-06-28
JP2019059790A (ja) 2019-04-18
JP2021001236A (ja) 2021-01-07
AU2008218186B2 (en) 2014-01-23
JP2011231132A (ja) 2011-11-17
TW200904419A (en) 2009-02-01
LTPA2016039I1 (lt) 2017-01-10
PT2487166T (pt) 2016-10-17
DK3150586T3 (da) 2020-02-17
EP2118082B1 (en) 2014-10-01
JP2016121193A (ja) 2016-07-07
HUE029843T2 (en) 2017-04-28
PT2118082E (pt) 2014-12-12
KR20150056665A (ko) 2015-05-26
CY1118292T1 (el) 2017-06-28
CY2017003I2 (el) 2017-06-28
LTC2487163I2 (lt) 2022-06-27
KR20090122261A (ko) 2009-11-26
JP2017171695A (ja) 2017-09-28
ES2779826T3 (es) 2020-08-20
EP2487161A1 (en) 2012-08-15
JP6192776B2 (ja) 2017-09-06
EP2487161B1 (en) 2016-08-10
ES2525454T3 (es) 2014-12-23
AU2008218186A1 (en) 2008-08-28
SG183059A1 (en) 2012-08-30
US8486942B2 (en) 2013-07-16
CY1118219T1 (el) 2017-06-28
JP2015078241A (ja) 2015-04-23
CY2020011I1 (el) 2020-11-25
HRP20161476T4 (hr) 2024-07-05
PT2487162T (pt) 2016-11-23
JP6147388B2 (ja) 2017-06-14
LUC00156I1 (es) 2020-06-02
US20160069915A1 (en) 2016-03-10
WO2008103949A1 (en) 2008-08-28
LTC2487162I2 (lt) 2022-06-27
JP4881446B2 (ja) 2012-02-22
PT2487163T (pt) 2016-11-21
SI3150586T1 (sl) 2020-03-31
TWI533868B (zh) 2016-05-21
US20140017199A1 (en) 2014-01-16
HUE029866T2 (en) 2017-03-28
PT2487161T (pt) 2016-11-10
LTPA2016038I1 (lt) 2017-01-10
LT2487163T (lt) 2016-10-25
IL200550A0 (en) 2010-05-17
US20120237478A1 (en) 2012-09-20
HRP20161428T1 (hr) 2016-12-16
NO2017002I1 (no) 2017-01-12
CN103435570A (zh) 2013-12-11
CY1118232T1 (el) 2017-06-28
FR20C1021I1 (fr) 2020-07-31
EP3150586B1 (en) 2020-01-08
CY2020011I2 (el) 2020-11-25
HK1137451A1 (en) 2010-07-30
LT3150586T (lt) 2020-03-10
DK2487166T3 (en) 2017-02-20
AP2013007042A0 (en) 2013-08-31
CY1122761T1 (el) 2020-11-25
LT2487166T (lt) 2016-11-10
ES2603617T3 (es) 2017-02-28
AP3915A (en) 2016-11-29
CN103435570B (zh) 2015-06-10
LTC2487166I2 (lt) 2021-10-11
US8148374B2 (en) 2012-04-03
CN101679325B (zh) 2013-08-28
KR101577698B1 (ko) 2015-12-15
CY2017002I2 (el) 2017-06-28
CN101679325A (zh) 2010-03-24
EP3150586A1 (en) 2017-04-05
LUC00156I2 (es) 2021-02-17
CA2678907C (en) 2014-06-17
US20170158647A1 (en) 2017-06-08
HRP20161502T1 (hr) 2016-12-16
AP2986A (en) 2014-09-30
NO2017003I1 (no) 2017-01-12
EP4403221A2 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
MX2009008935A (es) Moduladores de las propiedades farmacocineticas de productos terapeuticos.
WO2008010921A3 (en) Modulators of pharmacokinetic properties of therapeutics
PT2038290E (pt) Moduladores de receptor do tipo toll 7
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
UA94964C2 (ru) Производные 5-замещенного хиназолинона, композиция, которая их содержит, и их применение
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
MX2011011136A (es) Eteres diarilicos.
EP2613782A4 (en) INDAZOLE DERIVATIVES AS INHIBITORS OF THE ERK PATHWAY
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MY149622A (en) Pyrazoles as 11-beta-hsd-1
EP2054411A4 (en) NOVEL COMPOUNDS, ISOMERS THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
NZ593440A (en) Aminopyrazole compounds useful for inhibiting chk1
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2010001574A (es) Ligandos del receptor cannabinoide.
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
WO2009140341A3 (en) Atorvastatin compositions
TN2015000279A1 (en) Tricyclic compounds for inhibiting the cftr channel
MX2009003169A (es) Derivados de sulfonamida.

Legal Events

Date Code Title Description
FG Grant or registration